Sustainable approaches for drug repurposing in rare diseases: recommendations from the IRDiRC Task Force

Zanello, G; Ardigo, D; Guillot, F; Jonker, AH; Iliach, O; Nabarette, H; O'Connor, D; Hivert, V

Journal article

Sustainable approaches for drug repurposing in rare diseases: recommendations from the IRDiRC Task Force

Abstract:: Drug repurposing represents a real opportunity to address unmet needs and improve the lives of rare disease patients. It is often presented as a faster, safer and cheaper path for bringing drugs into new indications. However, several economic, regulatory and scientific barriers can impede the successful repurposing of drugs for rare diseases. The International Rare Diseases Research Consortium (IRDiRC) set up the Task Force on Sustainable Models in Drug Repurposing with the objective of identifying key factors for achieving sustainable repurposing approaches in rare diseases. In order to help inform expert opinion, the Task Force investigated six cases of medicinal products repurposed into new rare indications and four cases of ongoing development programs. A questionnaire addressing the major steps of the repurposing approach was developed by the Task Force and sent to contact points of the organizations. In addition, interviews were conducted with the relevant organization representatives to conduct a deeper dive into the sustainability of the repurposing approach for each of the selected cases. Based on the collective experience of the members of the Task Force and the output from the questionnaires/interviews, we have identified ten key factors that should be considered by those embarking on repurposing projects. These factors include the identification of unmet patient needs and partnership with patients, collection of evidence concerning disease prevalence, patient numbers, drug pharmacology and disease etiology, drug industrial property status, off-label or compounding use, data from past clinical studies and needs for extended non-clinical and clinical studies. The development of a collaborative funding framework and early discussion with regulators and payers are additional factors to implement early in the development of sustainable drug repurposing projects

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Zanello, G., Ardigo, D., Guillot, F., Jonker, A. H., Iliach, O., Nabarette, H., O'Connor, D., & Hivert, V. (2023). Sustainable approaches for drug repurposing in rare diseases: recommendations from the IRDiRC Task Force. Rare Disease and Orphan Drugs Journal, 2(2), 9–9.

MLA Style

Zanello, G, et al. “Sustainable Approaches for Drug Repurposing in Rare Diseases: Recommendations from the IRDiRC Task Force.” Rare Disease and Orphan Drugs Journal, vol. 2, no. 2, 2023, pp. 9–9.

Chicago Style

Zanello, G, D Ardigo, F Guillot, et al. 2023. “Sustainable Approaches for Drug Repurposing in Rare Diseases: Recommendations from the IRDiRC Task Force.” Rare Disease and Orphan Drugs Journal 2 (2): 9–9.
Print